Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
- Registration Number
- NCT01769781
- Lead Sponsor
- Centre for Endocrinology and Reproductive Medicine, Italy
- Brief Summary
The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.
- Detailed Description
Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing recurrence after surgery at least in 20-50% after 5 years of follow-up. Aromatase inhibitor plus GnRH analog may be more effective than GnRH agonist alone in the treatment of endometriosis recurrence.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 70
- women affected by endometriosis showing recurrence of pain symptoms, previous surgery for endometriosis
- presence of other systemic diseases
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description anastrazole anastrazole women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months GnRH analog alone GnRH analog alone women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
- Primary Outcome Measures
Name Time Method disease free time 24 months time without pain symptoms due to the disease recurrence
- Secondary Outcome Measures
Name Time Method time of pain disappearance 24 months time needed during treatment to improve pain symptoms
Trial Locations
- Locations (1)
Cerm-Hungaria
🇮🇹Rome, Italy